#ScienceLink #Madrid2026 #ESMO26 #lidERABC #Giredestrant
在 lidERA BC（III期；n=4170）中，患者报告结局分析显示，在 RE+/HER2− 早期 CM 中，辅助使用 giredestrant 可维持生活质量。
对照组：标准内分泌治疗（tamoxifeno 或芳香化酶抑制剂）。
⏰ 中位随访时间：32.3个月
📊 生活质量以及身体和角色功能：两组的平均评分均未出现具有临床意义的恶化。
💬 报告完全不感到副作用困扰的患者，giredestrant vs 标准治疗：
第3周期：53% vs 45%。
第24周期：54% vs 50%。
第42周期：51% vs 46%。
⚠️ 这些百分比对应于每次访视时填写问卷的受试者。这些结果不能证明生活质量具有优越性。
🔗 阅读/收听完整新闻：https://buff.ly/yRFDbwD
18 浏览 · 0 赞 · 0 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org来源：ScienceLink · x.com